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Abstract Purpose: To compare
the effects of two arginine vasopres-
sin (AVP) dose regimens on the
hemodynamic response, catechol-
amine requirements, AVP plasma
concentrations, organ function and
adverse events in advanced vasodila-
tory shock. Methods: In this
prospective, controlled, open-label
trial, patients with vasodilatory shock
due to sepsis, systemic inflammatory
response syndrome or after cardiac
surgery requiring norepinephrine
[0.6 lg/kg/min were randomized to
receive a supplementary AVP infu-
sion either at 0.033 IU/min (n = 25)
or 0.067 IU/min (n = 25). The
hemodynamic response, catechol-
amine doses, laboratory and organ
function variables as well as adverse
events (decrease in cardiac index or
platelet count, increase in liver
enzymes or bilirubin) were recorded
before, 1, 12, 24 and 48 h after ran-
domization. A linear mixed effects
model was used for statistical analysis
in order to account for drop-outs
during the observation period.
Results: Heart rate and
norepinephrine requirements
decreased while MAP increased in
both groups. Patients receiving AVP
at 0.067 IU/min required less norepi-
nephrine (P = 0.006) than those
infused with AVP at 0.033 IU/min.
Arterial lactate and base deficit
decreased while arterial pH increased
in both groups. During the observa-
tion period, AVP plasma levels
increased in both groups (both
P \ 0.001), but were higher in the
0.067 IU/min group (P \ 0.001) and
in patients on concomitant hydrocor-
tisone. The rate of adverse events and
intensive care unit mortality was
comparable between groups
(0.033 IU/min, 52%; 0.067 IU/min,
52%; P = 1). Conclusions: A sup-
plementary AVP infusion of
0.067 IU/min restores cardiovascular
function in patients with advanced
vasodilatory shock more effectively
than AVP at 0.033 IU/min.
Keywords Vasopressin  Dose 
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Introduction
Since 1997 [1], arginine vasopressin (AVP) has been used
as a supplementary vasopressor in patients with advanced
vasodilatory shock [2, 3]. While AVP repeatedly proved
effective in restoring cardiovascular function in shock
states poorly responsive or even resistant to catecholamine
therapy [1–7], no benefit of a supplementary AVP infusion
on septic shock survival was found in the Vasopressin in
Septic Shock Trial (VASST) [8]. Nonetheless, an a` priori
defined subgroup analysis suggested that AVP improved
outcome in patients with less severe septic shock [8] and in
those treated with concomitant low dose hydrocortisone
[9]. In the latest guidelines, the Surviving Sepsis
Intensive Care Med (2010) 36:57–65
DOI 10.1007/s00134-009-1630-1 ORIGINAL
Campaign suggests that AVP may be added as an adjunct
vasopressor agent when hemodynamic instability persists
despite escalating norepinephrine doses [10].
Although several clinical studies investigated the
effects of AVP in vasodilatory shock [1–7], little is
known about the optimal AVP dose to counteract vaso-
dilation. Identification of this AVP dose could help to
optimize hemodynamic effects while keeping adverse
effects at a minimum. So far, varying AVP doses between
0.01 and 2 IU/min have been used [1–7, 11]. In the
VASST study, AVP was infused at 0.01–0.03 IU/min [8].
The Surviving Sepsis Campaign recommends infusing
AVP at 0.03 IU/min [10]. However, no comparisons
between different AVP doses have yet been prospectively
investigated. So far, one retrospective analysis has eval-
uated the hemodynamic effects of two AVP doses and
observed that AVP at 0.067 IU/min was more effective to
reverse cardiovascular failure in advanced vasodilatory
shock than 0.033 IU/min [12].
We hypothesized that AVP at 0.067 IU/min could
restore cardiovascular function more effectively than
AVP at 0.033 IU/min. In this randomized, controlled,
open-label trial, the effects of two AVP doses (0.033 vs.
0.067 IU/min) on the hemodynamic response, organ
function and adverse events were prospectively compared
in advanced vasodilatory shock patients.
Patients and methods
This prospective, randomized, controlled, open-label
trial was performed in a 23-bed general and surgical
intensive care unit in a tertiary teaching hospital from 1
January 2008 until 31 December 2008. The study pro-
tocol was approved by the institutional review board
and the Ethics Committee of the Innsbruck Medical
University (UN 3052_LEK; EudraCT: 2007-005010-40).
Written informed consent was obtained from the
patients’ next of kin or the legal representative. In all
surviving patients, written informed consent was
obtained after recovery.
Inclusion and exclusion criteria
Critically ill patients were considered eligible to partici-
pate in the study if they presented with vasodilatory shock
due to sepsis, systemic inflammatory response syndrome
(SIRS) or cardiac surgery and required norepinephrine
doses [0.6 lg/kg/min to maintain MAP [60 mmHg.
Patients\18 years, in a moribund state unlikely to survive
[12 h, in whom intensive care therapy was withdrawn or
limited in an end-of-life decision, who received AVP or
any of its analogues because of other diagnoses than va-
sodilatory shock, participated in another clinical trial,
were pregnant or refused written informed consent were
excluded. Patients had to be included within 12 h after
their norepinephrine demand exceeded 0.6 lg/kg/min or
within 12 h after intensive care unit admission (in case
norepinephrine doses exceeded 0.6 lg/kg/min before
intensive care unit admission).
Definitions
Vasodilatory shock was defined as the simultaneous
presence of adequate systemic blood flow (cardiac
index [2–2.5 l/min/m2, mixed venous oxygen satura-
tion [60%, or an ejection fraction [50% together with a
heart rate [80 bpm in the absence of severe diastolic
dysfunction on echocardiography), a mean arterial blood
pressure (MAP) \60 mmHg in volume-resuscitated
patients together with a systemic vascular resistance
index \1,200 dyne*s/cm5*m2 resulting in the need for
norepinephrine [0.1 lg/kg/min for [12 h. Sepsis and
SIRS were defined according to the criteria suggested by
the American College of Chest Physicians and the Society
of Critical Care Medicine [13].
Hemodynamic management
Study patients were routinely monitored with an arterial
and central venous line. A pulmonary artery or transpul-
monary thermodilution catheter (PiCCO plus; Pulsion,
Munich, Germany) was inserted at the discretion of the
attending physician. Transesophageal echocardiography
was done at least once in all study patients for diagnostic
reasons and to guide hemodynamic management. Volume
resuscitation was performed according to the response of
filling pressures (e.g., central venous pressure, pulmonary
arterial occlusion pressure) and stroke volume/cardiac
index to repetitive fluid loading using gelatine-based
colloids (Gelofusin; B. Braun, Melsungen, Germany).
If the cardiac index remained \2–2.5 l/min/m2 or mixed
venous oxygen saturation\60% despite adequate volume
resuscitation and/or blood transfusion, milrinone (0.3–
0.7 lg/kg/min) and/or epinephrine was continuously
infused. After ensuring adequate systemic blood flow
using fluids and/or inotropes, norepinephrine (Arterenol;
Sanofi-Aventis, Frankfurt, Germany) was infused
to increase MAP [60–65 mmHg. Hydrocortisone
(200–300 mg/day) was added as a continuous infusion if
escalating norepinephrine doses could not stabilize
hemodynamic function. Intubated patients on mechanical,
assisted or spontaneous breathing were sedated by infusing
either sufentanil and midazolam, or morphine alone.
Continuous veno-venous hemofiltration was employed for
renal indications only. Causative and supportive sepsis
therapy was performed according to the Surviving Sepsis
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Campaign guidelines [10]. Activated protein C was not
administered.
Randomization and study groups
Based on a computer-generated list, patients were ran-
domly allocated to one of the two study groups. The first
group received AVP at 0.067 IU/min, while AVP was
infused at 0.033 IU/min in the second group. Clinicians
and researchers were not blinded to the study group
allocation. No bolus injections of AVP were given in any
group. After initiation of AVP (Pressyn; Ferring Inc,
Toronto, Canada), norepinephrine infusion was adapted to
maintain MAP [60–65 mmHg in both groups. If nor-
epinephrine could be decreased \0.2 lg/kg/min, AVP
was slowly tapered off at the discretion of the attending
physician. Simultaneously, norepinephrine doses could be
further reduced. No crossover between study groups was
allowed during the 48-h observation period.
Data collection
Demographic data, pre-existent chronic diseases, admis-
sion diagnosis, duration of AVP infusion, need for
continuous veno-venous hemofiltration, length of inten-
sive care unit stay, intensive care unit and 28-day
mortality were documented. A modified Goris multiple
organ dysfunction syndrome score [14] and the Sepsis-
related Organ Failure Assessment score [15] were calcu-
lated from most aberrant clinical and laboratory variables
during the intensive care unit stay.
The following hemodynamic variables were recorded
before, 1, 12, 24 and 48 h after randomization: heart rate,
MAP, central venous pressure, mean pulmonary arterial
pressure, pulmonary arterial occlusion pressure, cardiac
index, stroke volume index and mixed venous oxygen
saturation. Norepinephrine, epinephrine and milrinone
requirements were documented at the same intervals. The
systemic vascular resistance index was calculated using
the standard formula. Platelet count, plasma levels of
aspartate and alanine aminotransferase, total bilirubin,
creatinine, urea, troponin T, AVP and prolactin were
collected before, 24 and 48 h after the start of AVP ther-
apy. For hormone analyses, plasma samples were
immediately frozen at -70C and transferred to the
endocrinologic laboratory after completion of patient
recruitment. AVP levels were determined using a con-
ventional radioimmunoassay (DRG Diagnostics, Marburg,
Germany) [16]. Prolactin was measured with an enzyme-
linked immunosorbent assay (DRG Diagnostics, Marburg,
Germany). Hemoglobin levels, arterial pH, lactate con-
centrations, base deficit and the partial arterial oxygen
tension/fractional inspiratory oxygen concentration ratio
were recorded before, 1, 12, 24 and 48 h after
randomization. Occurrence of adverse events ([5%
increase in liver enzymes or total bilirubin levels or[5%
decrease in platelet count or cardiac index during the 48 h
observation period compared to randomization values)
was evaluated in all study patients.
Study endpoints
The primary endpoint was to compare the hemodynamic
response to AVP at two doses (0.033 vs. 0.067 IU/min).
Secondary endpoints included differences in organ func-
tion and laboratory variables, AVP and prolactin plasma
levels as well as the rate of adverse events.
Statistical analysis
Based on the results of a retrospective study [10], a
sample size of 22 patients per group was required to
detect a significant difference in the hemodynamic
response (MAP increase, norepinephrine decrease)
between AVP at 0.033 and 0.067 IU/min (alpha error,
0.05; beta error, 0.2; power, 80%).
The SPSS 13.0 software program (SPSS Inc; Chica-
geo, IL) was used for statistical analysis. Normality
distribution was assessed by the Kolmogorov–Smirnov
test. In case the normality assumption was not fulfilled
(aspartate and alanine aminotransferase, total bilirubin,
troponin T, AVP, prolactin), variables were ln-trans-
formed. All group comparisons were performed as
intention-to-treat analyses. The unpaired Student’s t
(continuous) or Fisher’s exact test (categorical) was used
to compare demographic and clinical parameters as well
as the rate of adverse events between groups. To compare
the hemodynamic response, changes in laboratory vari-
ables as well as plasma hormone levels over time between
groups, a linear mixed effects model was applied to
account for drop-outs during the observation period [17].
If hemodynamic and laboratory variables showed group
differences (P \ 0.1) before randomization, the baseline
value of the corresponding variable (stroke volume index,
cardiac index, systemic vascular resistance index, mixed
venous oxygen saturation, milrinone requirements) was
entered as a covariate into the mixed effects model.
P-values \0.05 were considered to indicate statistical
significance. All variables are given as mean values ±
SD, if not otherwise indicated.
Results
Sixty-one patients met the inclusion criteria during
the observation period, of which 50 patients were
enrolled (Fig. 1). A pulmonary artery or transpulmonary
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thermodilution catheter was in place in 16 and 13 patients
in the 0.033 and 0.067 IU/min group, respectively
(P = 0.57). All patients were included within 7 ± 5 h
after their norepinephrine requirements exceeded 0.6 lg/
kg/min or intensive care unit admission. There were no
differences in demographic and clinical variables between
groups before randomization (Table 1). Six patients in the
0.033 IU/min group and four patients in the 0.067 IU/min
group died during the observation period (P = 0.73).
Intensive care unit mortality was 52% (13/52) in both
groups (P = 1).
Heart rate (0.033 IU/min, P = 0.001; 0.067 IU/min,
P\0.001) and norepinephrine requirements (0.033 IU/min,
P = 0.03; 0.067 IU/min, P = 0.001) decreased, while
MAP increased in both groups (0.033 IU/min, P = 0.02;
0.067 IU/min, P \ 0.001) (Table 2). Patients receiving
AVP at 0.067 IU/min required less norepinephrine during
the study period when compared to the 0.033 IU/min
group. Throughout the study period, mixed venous
oxygen saturation was lower in the 0.033 than in the
0.067 IU/min group. While mixed venous oxygen satu-
ration remained unchanged in the 0.033 IU/min group
(P = 0.75), it tended to decrease in the 0.067 IU/min
group (P = 0.12). Simultaneous hydrocortisone therapy
did not influence the hemodynamic response to AVP in
both groups (both P [ 0.05).
Arterial lactate levels (0.033 IU/min, P = 0.05;
0.067 IU/min, P = 0.04) and base deficit (0.033 IU/min,
P \ 0.001; 0.067 IU/min, P = 0.001) decreased, while
arterial pH increased in both groups (0.033 IU/min,
P \ 0.001; 0.067 IU/min, P \ 0.001). Platelets fell in
both groups, but the decrease was only significant in
patients treated with 0.033 IU/min of AVP (0.033 IU/
min, P = 0.02; 0.067 IU/min, P = 0.18). Patients in the
0.067 IU/min group had lower plasma troponin levels
and base deficits than patients allocated to the 0.033 IU/
min group (Table 3). The rate of adverse events during
AVP infusion was comparable between groups
(Table 4).
AVP plasma levels increased in both groups (both
P \ 0.001) but were higher in the 0.067 IU/min group
(P \ 0.001) (Fig. 2). Study patients on concomitant
hydrocortisone therapy exhibited higher AVP levels than
patients who did not receive hydrocortisone in both
groups (Fig. 3). Prolactin plasma levels tended to increase
in both groups during AVP infusion (0.033 IU/min,
P = 0.05; 0.067 IU/min, P = 0.06). There was no dif-
ference in the course of prolactin plasma levels between
the two AVP groups (P = 0.98).
Discussion
The main findings of this randomized, controlled, open-
label trial were that a supplementary AVP infusion
increased MAP and decreased heart rate in advanced
vasodilatory shock irrespective of the dose infused.
The reduction of norepinephrine requirements was more
pronounced in patients treated with AVP at 0.067 than
0.033 IU/min. While the incidence of adverse events was
comparable between groups, base deficit and troponin
levels were higher in patients receiving AVP at
0.033 IU/min.
Randomized (n=50)
Fulfilled Inclusion Criteria
(n=61)
Exclusion Criteria (n=11)
Expected to die within 12 hours (n=7)
Refused to participate (n=2)
Other Exclusion Criteria (n=2)
AVP at 0.033 IU/min (n=25) AVP at 0.067 IU/min (n=25)
Analyzed (n (dezylanA)52= n=25)
Fig. 1 CONSORT protocol of
patient recruitment,
randomization and analysis
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As previously reported [1–7], an increase in MAP and
a reduction in heart rate as well as norepinephrine
requirements occurred in both groups after initiation of
AVP. Simultaneously, arterial pH, lactate levels and base
deficit improved, suggesting enhanced tissue perfusion.
Lower norepinephrine demands together with comparable
MAP levels confirm our hypothesis that 0.067 IU/min of
AVP could restore cardiovascular functions more effec-
tively than AVP at 0.033 IU/min. The lacking difference
in MAP between groups can be explained by the fact that
this variable was used to guide vasopressor therapy. The
results of the endocrinologic analysis revealed higher
AVP plasma levels in patients receiving 0.067 IU/min of
AVP than during AVP infusion at 0.033 IU/min. This
together with the finding that AVP plasma levels and
norepinephrine requirements in all study patients were
indirectly correlated (Spearman-rho correlation coeffi-
cient, -0.49; P \ 0.001) confirms dose-dependent
hemodynamic effects of AVP in vasodilatory shock.
So far, one retrospective analysis has addressed the
effects of different AVP doses in vasodilatory shock [12].
This analysis revealed similar results and was performed
in a comparable patient population. Including 78 subjects,
it suggested that patients treated with 0.067 IU/min of
AVP displayed a higher MAP and lower central venous
pressure, mean pulmonary arterial pressure and norepi-
nephrine requirements than patients receiving AVP at
0.033 IU/min [12]. The results of that and the present
study are in contrast to the findings of a case series in 50
septic shock patients [18]. In that analysis, Holmes et al.
reported adverse events in five patients treated with AVP
at doses [0.04 IU/min and concluded that AVP should
not be used at higher doses. Unlike the present trial, the
latter analysis was uncontrolled, observational and did not
prove a causative relationship between the occurrence of
adverse events and AVP doses [0.04 IU/min [18].
Even though our study included enough patients to
detect differences in the hemodynamic response between
groups, it was underpowered to investigate effects on
patient outcome. Since there is no proven link between
the duration of norepinephrine weaning and improved
outcome in septic or vasodilatory shock, no conclusions
on the effects of AVP doses on patient outcome can be
drawn from our results. So far, the multicentered VASST
trial was the only study investigating the effects of AVP
on mortality [8]. Considering that all study patients in our
trial suffered from ‘‘more severe’’ vasodilatory shock
(according to the VASST criteria), it is possible that AVP
doses applied in the VASST study (0.01–0.03 IU/min)
were too low. This hypothesis is supported by a recent
Table 1 Characteristics of the study population
0.033 IU/min 0.067 IU/min P-value
n 25 25
Age (years) 70 ± 15 64 ± 15 0.19
Male sex, n (%) 18 (72) 13 (52) 0.24
BMI (kg/m2) 26 ± 4 25 ± 4 0.40
Pre-existent diseases, n (%)
Chronic arterial hypertension 19 (76) 13 (52) 0.14
Coronary artery disease 12 (48) 8 (32) 0.39
Congestive heart failure 5 (20) 2 (8) 0.42
Chronic renal insufficiency 6 (24) 3 (12) 0.46
COPD 7 (28) 5 (20) 0.74
Malignant tumor disease 7 (28) 9 (36) 0.76
Admission diagnosis, n (%)
Septic shock 13 (52) 13 (52) 1
Vasodilatory shock after CS 3 (12) 3 (12) 1
Non-septic SIRS 9 (36) 9 (36) 1
Concomittant hydrocortisone, n (%) 13 (52) 14 (56) 1
CVVHF, n (%) 12 (48) 7 (28) 0.24
Goris MODS score (pts) 10.6 ± 1.2 10.6 ± 1.3 0.91
SOFA score (pts) 14.6 ± 2.5 15.1 ± 3.6 0.62
Duration of AVP infusion (h) 63 ± 40 56 ± 43 0.55
Length of ICU stay (days) 22 ± 18 17 ± 18 0.41
28-Day mortality, n (%) 10 (40) 13 (52) 0.57
ICU mortality, n (%) 13 (52) 13 (52) 1
BMI Body mass index, COPD chronic obstructive pulmonary dis-
ease, CS cardiac surgery, SIRS systemic inflammatory response
syndrome, CVVHF continuous venovenous hemofiltration, MODS
multiple organ dysfunction syndrome, SOFA sequential organ
failure assessment, ICU intensive care unit
Causes of non septic SIRS were multiple trauma (n = 5; AVP
0.033 IU/min, n = 3; AVP 0.067 IU/min, n = 2), severe
hemorrhage not related to multiple trauma (n = 6; AVP 0.033 IU/
min, n = 1; AVP 0.067 IU/min, n = 5), major surgery (n = 5;
AVP 0.033 IU/min, n = 3; AVP 0.067 IU/min, n = 2), pancrea-
titis (n = 1; AVP 0.033 IU/min, n = 1) and acute respiratory
failure (n = 1; AVP 0.033 IU/min, n = 1)
Data are given as mean values ± SD, if not indicated otherwise
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post hoc analysis of the VASST database indicating that
combined AVP and corticosteroid therapy was associated
with decreased mortality and organ dysfunction than
norepinephrine and corticosteroids [9]. In line with our
results, combined administration of low-dose corticoste-
roids and AVP resulted in higher AVP plasma levels than
infusion of AVP alone [9]. Although our data cannot
identify the mechanism for this observation, steroid-
induced inhibition of vasopressin degradation may be a
possible explanation.
Although higher AVP doses appear to allow more
rapid and pronounced reductions in norepinephrine
support, it is possible that such a dose regime induces
more adverse events thereby counterbalancing beneficial
cardiovascular effects. The results of the current trial
suggest that the rate of adverse events was not different
between the two AVP doses. It must, however, be con-
sidered that our patient population is too small to reliably
exclude differences in adverse events between groups.
The most important limitation of our analysis was that
important hemodynamic variables differed between
groups before randomization. Therefore, group compari-
sons over time had to be corrected for certain baseline
differences. Although this is an accepted statistical
Table 2 Hemodynamic response to arginine vasopressin in patients receiving 0.033 IU/min and 0.067 IU/min
Baseline 1 h 12 h 24 h 48 h P-value
n
0.033 IU/min 25 25 24 20 19
0.067 IU/min 25 25 24 21 21
AVP (IU/min)
0.033 IU/min 0 ± 0 0.033 ± 0 0.033 ± 0 0.033 ± 0 0.032 ± 0.04 \0.001*
0.067 IU/min 0 ± 0 0.067 ± 0 0.06 ± 0.02 0.057 ± 0.02 0.042 ± 0.03
HR (bpm)
0.033 IU/min 106 ± 22 104 ± 20 95 ± 19 89 ± 14 86 ± 11 0.94
0.067 IU/min 108 ± 17 101 ± 17 97 ± 14 87 ± 16 85 ± 21
MAP (mmHg)
0.033 IU/min 65 ± 9 71 ± 12 71 ± 11 71 ± 10 75 ± 7 0.66
0.067 IU/min 65 ± 9 78 ± 13 69 ± 14 71 ± 7 75 ± 7
CVP (mmHg)
0.033 IU/min 13 ± 4 13 ± 4 13 ± 4 12 ± 3 11 ± 3 0.52
0.067 IU/min 13 ± 4 13 ± 4 12 ± 3 11 ± 2 12 ± 3
MPAP (mmHg)
n = 10 0.033 IU/min 30 ± 5 29 ± 4 27 ± 7 26 ± 4 26 ± 3 0.89
n = 10 0.067 IU/min 29 ± 5 30 ± 5 27 ± 6 26 ± 5 26 ± 4
PAOP (mmHg)
n = 10 0.033 IU/min 18 ± 5 16 ± 5 17 ± 3 16 ± 5 18 ± 4 0.82
n = 10 0.067 IU/min 18 ± 6 18 ± 5 16 ± 5 16 ± 5 17 ± 5
CI (l/min/m2)
n = 16 0.033 IU/min 3.0 ± 1.1 2.6 ± 0.8 2.7 ± 0.8 2.9 ± 0.7 3.0 ± 0.8 0.29§
n = 13 0.067 IU/min 4.4 ± 1.9 4.3 ± 1.8 3.4 ± 1.1 3.3 ± 0.8 3.3 ± 0.8
SVI (ml/beat/m2)
n = 16 0.033 IU/min 30 ± 12 26 ± 10 31 ± 15 33 ± 10 36 ± 10 0.7§
n = 13 0.067 IU/min 41 ± 17 42 ± 17 35 ± 12 38 ± 10 38 ± 12
SVRI (dyne.s.cm-5/m2)
n = 16 0.033 IU/min 1492 ± 600 1925 ± 567 1844 ± 497 1656 ± 430 1813 ± 496 0.06§
n = 13 0.067 IU/min 1108 ± 492 1376 ± 560 1326 ± 617 1441 ± 301 1560 ± 549
SvO2 (%)
n = 10 0.033 IU/min 64 ± 13 n.a. n.a. 63 ± 10 66 ± 6 0.04*,§
n = 10 0.067 IU/min 76 ± 9 n.a. n.a. 72 ± 9 68 ± 9
Norepinephrine (lg/kg/min)
n = 25 0.033 IU/min 0.98 ± 0.6 0.94 ± 0.82 0.85 ± 0.96 0.57 ± 0.39 0.4 ± 0.31 0.006*
n = 25 0.067 IU/min 0.86 ± 0.34 0.64 ± 0.37 0.69 ± 0.78 0.65 ± 1.4 0.22 ± 0.16
Milrinone (lg/kg/min)
n = 17 0.033 IU/min 0.31 ± 0.21 0.37 ± 0.18 0.44 ± 0.19 0.42 ± 0.23 0.33 ± 0.2 0.38§
n = 13 0.067 IU/min 0.22 ± 0.17 0.2 ± 0.18 0.25 ± 0.25 0.28 ± 0.24 0.23 ± 0.16
Epinephrine (lg/kg/min)
n = 11 0.033 IU/min 0.03 ± 0.04 0.04 ± 0.04 0.08 ± 0.05 0.07 ± 0.06 0.06 ± 0.03 0.85
n = 12 0.067 IU/min 0.06 ± 0.08 0.17 ± 0.53 0.08 ± 0.07 0.08 ± 0.14 0.05 ± 0.02
AVP Arginine vasopressin, HR heart rate, MAP mean arterial blood
pressure, CVP central venous pressure, MPAP mean pulmonary
arterial blood pressure, PAOP pulmonary artery occlusion pressure,
CI cardiac index, SVI stroke volume index, SVRI systemic vascular
resistance index, SvO2 mixed venous oxygen saturation, n.a. not
available
Data are given as mean values ± SD, if not indicated otherwise
*Significant difference over time between groups, § corrected for
baseline differences
62
method to compensate for group differences at randomi-
zation, it limits data interpretation. In our trial, this is
particularly relevant for interpreting differences in heart
function between the two study groups. It appears that
patients allocated to the 0.033 IU/min group suffered
from more chronic heart diseases. This could explain
why at randomization indices of systemic blood flow
were lower and milrinone requirements higher in this
group when compared to patients receiving AVP at
0.067 IU/min. Accordingly, these baseline differences do
not allow drawing firm clinical conclusions on the effects
of the two AVP dose regimes on heart function. However,
the observation that troponin levels increased in patients
receiving lower AVP doses while they remained
unchanged in the 0.067 IU/min group may point at ben-
eficial effects of a more pronounced reduction of
norepinephrine infusion and by that adrenergic stress on
the heart [19, 20]. However, this finding must be
Table 3 Changes in organ function variables in study groups
Baseline 1 h 12 h 24 h 48 h P-value
Hemoglobin (mg/dl)
0.033 IU/min 10.7 ± 1.6 10.3 ± 1.4 10.3 ± 1.4 10.5 ± 1.9 9.9 ± 1.2 0.39
0.067 IU/min 10.2 ± 1.1 10.5 ± 1.2 10.1 ± 1.3 10 ± 1 10 ± 1.3
Platelets (G/ll)
0.033 IU/min 134 ± 80 n.a. n.a. 92 ± 57 81 ± 47 0.52
0.067 IU/min 129 ± 85 n.a. n.a. 99 ± 98 78 ± 92
ASAT (IU/l)
0.033 IU/min 746 ± 2146 n.a. n.a. 915 ± 2091 340 ± 415 0.91
0.067 IU/min 344 ± 677 n.a. n.a. 552 ± 814 582 ± 1136
ALAT (IU/l)
0.033 IU/min 443 ± 1340 n.a. n.a. 547 ± 1365 250 ± 467 0.98
0.067 IU/min 216 ± 542 n.a. n.a. 292 ± 466 319 ± 675
Total bilirubin (mg/dl)
0.033 IU/min 2.6 ± 4.6 n.a. n.a. 2.6 ± 4.7 2.8 ± 5.6 0.56
0.067 IU/min 2.8 ± 3.4 n.a. n.a. 2.4 ± 2.5 2.4 ± 2.8
Creatinine (mg/dl)
0.033 IU/min 1.9 ± 0.5 n.a. n.a. 1.9 ± 0.6 1.9 ± 0.7 0.09
0.067 IU/min 1.8 ± 0.9 n.a. n.a. 1.6 ± 0.7 1.6 ± 0.8
Urea (mg/dl)
0.033 IU/min 97 ± 49 n.a. n.a. 102 ± 55 109 ± 54 0.08
0.067 IU/min 88 ± 47 n.a. n.a. 82 ± 27 95 ± 40
Troponin T (mg/dl)
0.033 IU/min 0.63 ± 1.62 n.a. n.a. 0.57 ± 0.93 1.77 ± 4.8 0.03*
0.067 IU/min 0.17 ± 0.33 n.a. n.a. 0.17 ± 0.23 0.22 ± 0.41
Arterial pH
0.033 IU/min 7.30 ± 0.11 7.29 ± 0.10 7.31 ± 0.10 7.36 ± 0.07 7.42 ± 0.08 0.55
0.067 IU/min 7.33 ± 0.09 7.32 ± 0.09 7.34 ± 0.12 7.37 ± 0.08 7.44 ± 0.05
Base deficit (mmol/l)
0.033 IU/min -4.5 ± 4.7 -5.4 ± 5.1 -4.2 ± 4.5 -1.2 ± 3.7 2.5 ± 4.3 0.03*
0.067 IU/min -2.3 ± 5.5 -3.1 ± 5.6 -3.2 ± 6 0 ± 5.2 3.1 ± 5.1
Arterial lactate (mg/dl)
0.033 IU/min 36 ± 26 42 ± 39 49 ± 47 33 ± 26 19 ± 13 0.24
0.067 IU/min 49 ± 45 51 ± 45 55 ± 56 34 ± 27 21 ± 15
paO2/FiO2
0.033 IU/min 179 ± 79 191 ± 89 190 ± 104 217 ± 98 230 ± 78 0.4
0.067 IU/min 191 ± 95 185 ± 87 173 ± 75 197 ± 69 212 ± 75
ASAT Aspartate aminotransferase, ALAT alanine aminotransferase,
paO2 arterial oxygen partial pressure, FiO2 inspiratory oxygen
concentration, n.a. not available
*Significant difference over time between groups
Table 4 Adverse events during
AVP therapy 0.033 IU/min 0.067 IU/min P-value
Decrease in cardiac index, n (%) 4 (25) 7 (50) 0.26
Increase in serum transaminases, n (%) 10 (47.6) 15 (65.2) 0.36
Increase in total bilirubin, n (%) 4 (19) 6 (26.1) 0.72
Decrease in platelet count, n (%) 15 (71.4) 17 (73.9) 1
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considered preliminary and hypothesis-generating, since
future trials are required to further elucidate this endpoint.
Similarly, it is unclear whether decreasing mixed venous
oxygen saturation in the 0.067 IU/min group represented
reversal of hyperdynamic blood flow or a clinically rel-
evant reduction of systemic oxygen supply.
A strength of this clinical investigation is its ran-
domized, controlled design. Only few patients could not
be enrolled because either exclusion criteria were present
or written informed consent was denied suggesting min-
imal selection bias [21]. In accordance with results of the
power analysis, the trial included an adequate number of
patients to uncover differences in the hemodynamic
response between the two AVP doses. The fact that study
group allocation was not blinded is a weakness of our
study, and we cannot exclude that a treatment-bias orig-
inating from the open-label design has influenced the
study results. Since the majority of patients in both study
groups were either on continuous veno-venous hemofil-
tration or received diuretics during the observation period,
we could not compare the effects of different AVP dose
regimes on urine output and net fluid balance. Further-
more, it is impossible to assess whether the preference of
dobutamine as the first-line inotrope and use of activated
protein C would have been more effective to resuscitate
our study patients.
In conclusion, a supplementary AVP infusion of
0.067 IU/min can restore cardiovascular function in
advanced vasodilatory shock more effectively than AVP
at 0.033 IU/min. Future trials including more patients are
warranted to evaluate the effects of AVP at 0.067 IU/min
on the overall outcome of patients with advanced
vasodilatory shock secondary to systemic inflammation.
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Fig. 2 Arginine vasopressin and prolactin plasma levels in patients
receiving AVP at 0.033 IU/min (dots) and 0.067 IU/min (squares).
AVP plasma levels increased in both study groups (both
P \ 0.001). The increase was more pronounced in patients
receiving AVP at 0.067 IU/min (squares) when compared to
patients receiving AVP at 0.033 IU/min (dots) (P \ 0.001). There
was no group difference in prolactin plasma levels (P = 0.98).
Absolute values of AVP (pmol/l) were: 0 h: 0.033 IU/min, 15.9 ±
24.7; 0.067 IU/min, 13.9 ± 6.3; 24 h: 0.033 IU/min, 114.7 ± 56.2;
0.067 IU/min, 262 ± 138.2; 48 h: 0.033 IU/min, 98.8 ± 46;
0.067 IU/min, 216.5 ± 125.7
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Fig. 3 Arginine vasopressin plasma levels in patients with (trian-
gle) and without concomitant hydrocortisone therapy (diamond) in
both study groups. Arginine vasopressin (AVP) plasma levels
significantly increased in both groups after start of AVP therapy
(both P \ 0.001), but the increase was more pronounced if
patients received a concomitant hydrocortisone therapy (AVP
0.033 IU/min, P = 0.05; AVP 0.067 IU/min, P = 0.04). Absolute
values of AVP (pmol/l) were: AVP 0.033 IU/min: 0 h: no HC,
9.8 ± 7.9; HC, 21.5 ± 33.1; 24 h: no HC, 103.3 ± 72.8; HC,
123.9 ± 39.2; 48 h: no HC, 100.6 ± 56.1; HC, 97.3 ± 39.3; AVP
0.067 IU/min: 0 h: no HC, 12.5 ± 5.9; HC, 15.1 ± 6.7; 24 h: no
HC, 216.5 ± 128.1; HC, 318.9 ± 136.6; 48 h: no HC, 191.9 ±
123.1; HC, 234.9 ± 132.8
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